Table 1.
Baseline characteristics of patient cohorts
| Training N = 203 (%) | Validation N = 84 (%) | p-value | |
|---|---|---|---|
| Age (median) | 46.4 ± 10.2 | 46.1 ± 11.0 | 0.308 |
| Range | 23.5-74.1 | 22.4 – 74.0 | |
| < 40 years | 48 (23.6) | 28 (33.3) | |
| ≥ 40 years | 155 (76.4) | 56 (66.7) | |
| Histology | 0.654 | ||
| IDCa | 180 (88.7) | 76 (90.5) | |
| Others | 23 (11.3) | 8 (9.5) | |
| Stage | <0.001 | ||
| I | 55 (27.1) | 15 (17.9) | |
| IIA | 94 (46.3) | 18 (21.4) | |
| IIB | 33 (16.3) | 9 (11.9) | |
| IIIA | 13 (6.4) | 26 (31.0) | |
| IIIB | 0 (0) | 1 (1.2) | |
| IIIC | 8 (3.9) | 14 (16.7) | |
| Unknown | 0 (0) | 1 (1.2) | |
| Nuclear grade | 0.191 | ||
| 1 | 2 (1.0) | 0 (0) | |
| 2 | 47 (23.2) | 18 (21.4) | |
| 3 | 145 (71.4) | 57 (67.9) | |
| Unknown | 9 (4.4) | 9 (10.7) | |
| Histologic grade | 0.411 | ||
| 1 | 3 (1.5) | 1 (1.2) | |
| 2 | 45 (22.2) | 20 (23.8) | |
| 3 | 144 (70.9) | 54 (64.3) | |
| Unknown | 11 (5.4) | 9 (10.7) | |
| RNA expression (log2 scale, median) | |||
| EGFR | 7.0 ± 1.1 | 7.6 ± 1.2 | 0.456 |
| ERBB2 | 9.0 ± 1.0 | 9.4 ± 1.6 | 0.439 |
| ERBB3 | 7.2 ± 1.0 | 7.7 ± 1.0 | 0.503 |
| ERBB4 | 1.3 ± 1.4 | 2.3 ± 2.2 | 0.302 |
| ESR1 | 4.4 ± 0.1 | 4.5 ± 2.0 | 0.425 |
| Chemotherapy | NA | ||
| Adjuvant | 203 (100) | 60 (71.4) | |
| Neoadjuvant | 0 (0) | 24 (28.6) | |
| Unknown | 0 (0) | 0 (0) | |
| Regimen | NA | ||
| CMF1 | 86 (42.4) | 10 (11.9) | |
| FAC2 | 58 (28.6) | 16 (19.0) | |
| AC3 | 17 (8.4) | 5 (6.0) | |
| AC –T(H)4 | 41 (20.2) | 46 (54.8) | |
| Hormone | 0 (0) | 0 (0) | |
| Unknown | 1 (0.5) | 7 (8.3) | |
| Adjuvant RTx5 | 0.161 | ||
| Yes | 130 (64.0) | 61 (72.6) | |
| No | 73 (36.0) | 23 (27.4) |
aInvasive ductal carcinoma, 1Cyclophosphamide/Methotrexate/Fluorouracil, 2Fluorouracil/Adriamycin/Cyclophosphamide, 3Adriamycin/Cyclophosphamide, 4Taxane (Herceptin), 5Radiotherapy